logo-loader
LSE:RENE FRA:RQE1

ReNeuron Group PLC

Market:
LSE
Market Cap:
£27.57 m
Price
86.50 GBX
Change
2.98%
52 weeks high
297.50
52 weeks low
71.00

In brief

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

Deep dive We explore the investor case for growth companies

Snapshot

  • Developer of stem cell technologies
  • Has two clinical stage technologies
  • Stroke treatment in Phase IIb trials

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Are small-cap biotech stocks good investments now?

We look at the sector's success stories and assess what we can expect in the coming months

on 14/8/20